Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY | Market Cap | 6.81T |
| Revenue (ttm) | 4.48T |
| Net Income (ttm) | 136.92B |
| Shares Out | 1.56B |
| EPS (ttm) | 85.30 |
| PE Ratio | 51.12 |
| Forward PE | 29.01 |
| Dividend | 200.00 (4.58%) |
| Ex-Dividend Date | Sep 29, 2025 |
| Volume | 2,253,700 |
| Average Volume | 4,964,820 |
| Open | 4,420.00 |
| Previous Close | 4,361.00 |
| Day's Range | 4,375.00 - 4,434.00 |
| 52-Week Range | 3,916.00 - 4,670.00 |
| Beta | 0.26 |
| RSI | 46.59 |
| Earnings Date | Oct 30, 2025 |
About TYO:4502
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]
Full Company ProfileFinancial Performance
In 2024, TYO:4502's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.
Financial StatementsNews
Takeda Pharmaceutical to exit cell therapy research
Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a partner to advance candidates under development.
Bristol Myers, Takeda to pool data for AI-based drug discovery
Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and develop...
TAK Makes Notable Cross Below Critical Moving Average
In trading on Tuesday, shares of Takeda Pharmaceutical Co Ltd (Symbol: TAK) crossed below their 200 day moving average of $14.46, changing hands as low as $14.41 per share. Takeda Pharmaceutical Co Lt...
Shares of Asian drugmakers drop after Trump threatens tariffs
Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...
Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually
Takeda (TAK) offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class candidates, but ...
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) part...
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical compan...
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, eff...
Takeda Pharmaceutical Company Limited (TAK) Special Call - Slideshow
Takeda Pharmaceutical Co Ltd (TAK) Announces Promising Phase 3 Trial Results for Oveporexton in ...
Takeda Pharmaceutical Co Ltd (TAK) Announces Promising Phase 3 Trial Results for Oveporexton in Treating Narcolepsy Type 1 | TAK stock news
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a...
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applicatio...
What's Going On With Takeda Stock On Friday?
On Friday, Takeda Pharmaceutical Co Ltd's (NYSE: TAK) stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday. On Thursda...
What's Going On With Takeda Stock On Friday?
On Friday, Takeda Pharmaceutical Co Ltd's TAK stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.
Japan's Takeda weighs India for global trials to speed up drug launches
Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting global clinical trials in India to accelerate the launch of its innovative drugs in the world's most populous nation, its...
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its m...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
Takeda Pharmaceutical Company Limited (NYSE: TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), ref...
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
Takeda Pharmaceutical Company Limited TAK posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a...
Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript
Takeda Pharmaceutical Non-GAAP EPS of ¥151.00, revenue of ¥1106.7B; reaffirms FY outlook
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVAN...